- InnoCare Pharma and KeyMed Biosciences have entered an exclusive license agreement with Prolium Bioscience for the development of ICP-B02.
- The deal includes payments of up to $520 million, with potential royalties based on future sales.

InnoCare Pharma and KeyMed Biosciences have announced an exclusive partnership with Prolium Bioscience to develop and commercialise ICP-B02 (CM355), a promising CD20xCD3 bispecific antibody. This agreement covers the non-oncology field globally and the oncology field in regions outside of Asia.
ICP-B02 is designed to bind to CD20 on tumour cells and CD3 on T cells, redirecting and activating T cells to eliminate tumour cells through T-cell Directed Cellular Cytotoxicity (TDCC). The therapy has shown strong potential in both oncology and non-oncology applications.
The agreement will see Prolium obtaining exclusive rights to develop, manufacture, and commercialise ICP-B02 in the specified regions. InnoCare and KeyMed will receive aggregate payments of up to $520 million, including upfront payments and additional amounts tied to the achievement of clinical, regulatory, and commercial milestones. Additionally, they will acquire a minority equity stake in Prolium and be entitled to tiered royalties on future net sales.
Prolium is supported by RTW Investments, LP, a global investment firm that identifies disruptive innovations in the biopharmaceutical and medical technology sectors. This partnership positions InnoCare and KeyMed to benefit from Prolium’s expertise in the global biopharmaceutical market.